Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of rZIKV/D4Δ30-713
NCT03611946Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2018
- Primary completion
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rZIKV/D4Δ30-713 in Zika virus infection (4 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants With Solicited Local and General Adverse Events at Day 28 and Immunogenicity of a Single Dose of rZIKV/D4Δ30-713 at Day 28. Started Jul 2018; status: completed.
02
Drugs
rZIKV/D4Δ30-713
03
Conditions
Zika virus infection
Beyond the preview
Go deeper on NCT03611946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03611946.